Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INO-464 + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Innocrin
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
INO-464 (seviteronel) is an orally bioavailable dual inhibitor of cytochrome P450c17a (CYP17) 17,20-lyase and androgen receptor (AR), developed for the treatment of hormone-driven cancers such as metastatic castration-resistant prostate cancer. It competitively inhibits both wild-type and mutated forms of the AR and selectively targets CYP17 lyase over hydroxylase activity[10]. Nab-paclitaxel is a nanotechnology-based formulation of paclitaxel bound to albumin nanoparticles, designed to improve solubility and delivery. It acts as a microtubule inhibitor that disrupts cell division in cancer cells[2][9]. The combination "INO-464 + nab-paclitaxel" represents an investigational regimen combining hormonal pathway inhibition with cytotoxic chemotherapy for enhanced antitumor efficacy.
- Brand names
- Abraxane
- Other names
- nanoparticle albumin-bound paclitaxelalbumin-bound paclitaxel
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)TUBB (Tubulin (alpha and beta subunits))AR (Adrenergic receptors)
Beyond the preview
Go deeper on INO-464 + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INO-464 + nab-paclitaxel.